Beneficial long-term antidiabetic actions of N- and C-terminally modified analogues of apelin-13 in diet-induced obese diabetic mice
Journal article
Authors | Parthsarathy, Vadivel, Hogg, Christopher, Flatt, Peter R. and O'Harte, Finbarr P. M. |
---|---|
Abstract | To investigate the chronic effects of twice-daily administration of stable apelin analogues, apelin-13 amide and pyroglutamyl (pGlu) apelin-13 amide, on metabolic variables in glucose-intolerant and insulin-resistant diet-induced obese mice fed a high-fat diet for 150 days. Groups of mice received twice-daily (9 am and 5 pm) injections of saline vehicle, apelin-13 amide, (pGlu)apelin-13 amide or exendin-4(1-39) for 28 days (all at 25 nmol/kg). Energy intake, body weight, non-fasting blood glucose, plasma insulin, glucose tolerance, metabolic response to feeding and insulin sensitivity, together with pancreatic hormone content and biochemical variables such as lipids and total GLP-1 were monitored. Dual-energy X-ray absorptiometry analysis and indirect calorimetry were also performed. Administration of apelin-13 amide, (pGlu)apelin-13 amide or exendin-4 significantly decreased body weight, food intake and blood glucose and increased plasma insulin compared with high-fat-fed saline-treated controls (P < .05 and P < .001), Additionally, all peptide-treated groups exhibited improved glucose tolerance (oral and intraperitoneal), metabolic responses to feeding and associated insulin secretion. (pGlu)apelin-13 amide also significantly improved glycated haemoglobin and insulin sensitivity after 28 days. Both (pGlu)apelin-13 amide and exendin-4 increased bone mineral content and decreased respiratory exchange ratio, whereas only (pGlu)apelin-13 amide increased energy expenditure. All treatment groups displayed reduced circulating triglycerides and increased glucagon-like peptide-1 concentrations, although only (pGlu)apelin-13 amide significantly reduced LDL cholesterol and total body fat, and increased pancreatic insulin content. These data indicate the therapeutic potential of stable apelin-13 analogues, with effects equivalent to or better than those of exendin-4. |
Keywords | adipokine; apelin analogues; diabetes; obesity; satiety |
Year | 2017 |
Journal | Diabetes Obesity and Metabolism |
Journal citation | 20 (2), pp. 319-327 |
Publisher | Wiley |
ISSN | 14628902 |
Digital Object Identifier (DOI) | https://doi.org/10.1111/dom.13068 |
Web address (URL) | http://hdl.handle.net/10545/624633 |
hdl:10545/624633 | |
http://europepmc.org/article/med/28730728 | |
https://pure.ulster.ac.uk/en/publications/beneficial-long-term-antidiabetic-actions-of-n-and-c-terminally-m-2 | |
http://doi.wiley.com/10.1111/dom.13068 | |
Output status | Published |
Publication dates | |
Online | 20 Jul 2017 |
Publication process dates | |
Deposited | 01 Apr 2020 |
Accepted | 01 Jul 2017 |
Rights | Archived with thanks to Diabetes, Obesity and Metabolism |
Contributors | University of Ulster, School of Biomedical Sciences, SAAD Centre for Pharmacy and Diabetes; University of Ulster; Coleraine Northern Ireland, UK, School of Biomedical Sciences, SAAD Centre for Pharmacy and Diabetes; University of Ulster; Coleraine Northern Ireland, UK, School of Biomedical Sciences, SAAD Centre for Pharmacy and Diabetes; University of Ulster; Coleraine Northern Ireland, UK and School of Biomedical Sciences, SAAD Centre for Pharmacy and Diabetes; University of Ulster; Coleraine Northern Ireland, UK |
File | File Access Level Open |
https://repository.derby.ac.uk/item/941z7/beneficial-long-term-antidiabetic-actions-of-n-and-c-terminally-modified-analogues-of-apelin-13-in-diet-induced-obese-diabetic-mice
Download files
39
total views0
total downloads5
views this month0
downloads this month